Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

>> Preview...

Boehringer Ingelheim Building $69 Million Plant in China Medical City

publication date: Jun 1, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Boehringer Ingelheim will invest $69 million into a veterinary vaccine medicine production facility, which will be built in Taizhou China Medical City. The new manufacturing plant follows closely on BI’s $15 million investment into an animal health R&D lab in Shanghai’s Zhangjiang Hi-Tech park, which opened in March of this year. The company wants to increase its market share in the Asia-specific animal vaccine sector. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
  Subscribe 
Forgot password?
>> Login help...
ChinaBio® Events

ChinaBio® Partnering Forum 2013
  May 29-30, 2013
Beijing, China

>>More events...
Partner Events

China Medical Affairs Summit
  June 18-19, 2013
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners